Efficacy and safety of furmonertinib in osimertinib-resistant patients with advanced non-small cell lung cancer:16 cases
Objective:To evaluate the efficacy and safety of furmonertinib in treating osimertinib-resistant patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor(EGFR)mutations.Methods:A retrospective analysis of clinical data was conducted in osimertinib-resistant patients with NSCLC,who were administered furmonertinib 160 mg daily from April 2021 to February 2023.The efficacy and safety were evaluated accordingly.Results:A total of 16 patients(13 females;median age 62.5)were enrolled in this analysis.The patients stopped the treatment until the occurrence of disease process or intolerant adverse reactions.Objective response rate was 0%,disease control rate was 75%,and median progression-free survival was 4 months.Treatment-related adverse events occurred in10 patients(62.5%),including grades1～2 diarrhea and dermatologic toxicities.No patient discontinued furmonertinib due to adverse events.Conclusion:High-dose furmonertinib 160 mg daily had high disease control rate in osimertinib-resistant NSCLC patients,and toxicity is manageable.
NETL
NSTL
万方数据
维普
